[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![SanCompounding Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1000030068452876288.png) Sandeep Anand [@SanCompounding](/creator/twitter/SanCompounding) on x 2787 followers
Created: 2025-07-26 14:08:26 UTC

BIG TAM OPENING UP FOR $HIMS :: 

This is why $HIMS is expanding into International Markets like CA, AU. Might soon enter Brazil and India to tap into the GLP-1 generic white space.

The core patent for semaglutide, the active ingredient in Ozempic, is set to expire in several countries in 2026—

🇨🇳Specifically, the patent is expiring in China on March 20, 2026. 

🇨🇦In Canada, the main protection is set to expire on January 4, 2026

🇧🇷Patents are expiring in Brazil, and India in 2026. 

While the US and Europe have longer patent protection till 2031, these 2026 expirations are expected to lead to the launch of generic versions.

The best part— $HIMS is today valued for just US Addressable Market. Huge potential unwrapping in International markets

![](https://pbs.twimg.com/media/Gwyg0DFWQAA28Hz.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1949109559336792239/c:line.svg)

**Related Topics**
[hims](/topic/hims)
[canada](/topic/canada)
[china](/topic/china)
[countries](/topic/countries)
[ozempic](/topic/ozempic)
[india](/topic/india)
[brazil](/topic/brazil)
[$hims](/topic/$hims)

[Post Link](https://x.com/SanCompounding/status/1949109559336792239)